Trastuzumab associated with durable EFS in HER-2–positive breast cancer

  • April 17, 2014

Patients with locally advanced or inflammatory HER-2–positive breast cancer who underwent neoadjuvant chemotherapy plus trastuzumab followed by adjuvant trastuzumab demonstrated durable EFS, according to updated phase 3 study results.

The analysis included 235 patients with HER-2–positive breast cancer. Of these patients, 118 received chemotherapy alone, and 117 received chemotherapy plus trastuzumab (Herceptin, Genentech) for 1 year before and after surgery. Ninety-nine patients with HER-2–negative disease who were included in a parallel cohort received neoadjuvant chemotherapy alone.

Full Story »
  • Filter By:

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More»
More»
More »
More»